The role of prostate-specific antigen velocity in prostate cancer early detection

Current Urology Reports

Volumn 1, Issue 1, 2000, Pages 15-19

  Potter, Steven R ^a   Carter, H Ballentine ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Benign Prostatic Hyperplasia; Minimum Elapse Time; National Comprehensive Cancer Network; Prostate Cancer; Prostate Cancer Early Detection

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; HUMAN; MALE; PROSTATE TUMOR; REVIEW; TIME;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0034191146     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-000-0030-4     Document Type: Article

References (36)

1. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990, 194:755–763. DOI: 10.1111/j.1432-1033.1990.tb19466.x
2. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK: Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974–1994. J Urol 1997, 158:1427–1430. DOI: 10.1016/S0022-5347(01)64231-9
3. Gann PH: Interpreting recent trends in prostate cancer incidence and mortality. Epidemiology 1997, 8:117–120.
4. Catalona WJ, Richie JP, Ahmann FR, et al.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994, 151:1283–1290.
5. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995, 273:289–294. DOI: 10.1001/jama.273.4.289
6. Eyre HJ, Feldman GE: Status report on prostate cancer in African-Americans: a national blueprint for action. CA Cancer J Clin 1998, 48:315–319.
7. Farkas A, Schneider D, Perrotti M, et al.: National trends in epidemiology of prostate cancer, 1973–1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998, 52:444–448. The authors compile epidemiologic data detailing the effects of PSA-based screening programs on prostate cancer incidence and stage migration. DOI: 10.1016/S0090-4295(98)00242-8
8. Mettlin C, Jones G, Averett H et al.: Defining and updating the American Cancer Society guidelines for the cancer-related checkup. Prostate and endometrial cancers. CA Cancer J Clin 1993, 43:42–46.
9. American Urological Association Policy Statement. Early Detection of Prostate Cancer and Use of Transrectal Ultrasound. Policy Statement Book. Baltimore:American Urological Association; 1992:4–20.
10. Potter SR, Partin AW: National Comprehensive Cancer Network Practice guidelines for early detection of prostate cancer. Oncology 1999, 13:99–115. The authors provide a cogent review of issues surrounding efforts at prostate cancer early detection in reporting the guidelines of the National Comprehensive Cancer Network.
11. Carter HB, Partin AW: Diagnosis and staging of prostate cancer. In Campbell’s Urology, vol 3, edn 7. Edited by Walsh PC, Retik AB, Vaughan ED, Wein AJ. Philadelphia:WB Saunders; 1998:2519–2537.
12. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993, 270:948–954. DOI: 10.1001/jama.270.8.948
13. Littrup PJ, Kane RA, Mettlin CJ, et al.: Cost-effective prostate cancer detection. Reduction if low-yield biopsies. Investigators of the American Cancer Society National Prostate Detection Project. Cancer 1994, 74:3146–3158. DOI: 10.1002/1097-0142(19941215)74:12<3146::AID-CNCR2820741214>3.0.CO;2-Z
14. Ercole CJ, Lange PH, Mathiesen M, et al.: Prostate-specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987, 138:1181–1184.
15. Nadler RB, Humphrey PA, Smith DS, et al.: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels. J Urol 1993, 154:407–413. DOI: 10.1016/S0022-5347(01)67064-2
16. Nixon RG, Brawer MK: Enhancing the specificity of prostatespecific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br J Urol 1997, 79(suppl 1):61–67.
17. Stamey TA, Yang N, Hay AR, et al.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 143:1146–1154.
18. Partin AW, Carter HB, Chan DW, et al.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990, 143:747–752.
19. Stamey TA, Kabalin JN, Ferrari M: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989, 141:1076–1083.
20. Meyer JS, Sufrin G, Martin SA: Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J Urol 1982, 128:1353–1356.
21. Carter HB, Pearson JD: Evaluation of changes in PSA in the management of men with prostate cancer. Semin Oncol 1994, 21:554–559.
22. Schock NW, Greulich RC, Andres R, et al.: Normal Human Aging: the Baltimore Longitudinal Study of Aging. Washington, DC: National Institutes of Health, publication no. 84-2450. United States Government Printing Office; 1984.
23. Gormley GJ, Stoner E, Bruskewitz RC, et al.: The effect of Finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327:1185–1191. DOI: 10.1056/NEJM199210223271701
24. Carter HB, Pearson JD, Metter EJ, et al.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JaMA 1992, 267:2215–2220. DOI: 10.1001/jama.267.16.2215
25. Pearson JD, Carter HB: Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994, 152:1743–1758.
26. Carter HB, Pearson JD, Waclawiw Z, et al.: Prostate-specific antigen variability in men without prostate cancer: the effect of sampling interval and number of repeat measurements on prostate-specific antigen velocity. Urology 1995, 45:591–595. DOI: 10.1016/S0090-4295(99)80049-1
27. Carter HB, Pearson JD: Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 1997, 24:333–338. DOI: 10.1016/S0094-0143(05)70380-3
28. Kadmon D, Weinberg AD, Williams RH, et al.: Pitfalls in interpreting prostate specific antigen velocity. J Urol 1996, 155:1655–1657. DOI: 10.1016/S0022-5347(01)66154-8
29. Komatsu K, Wehner N, Prestigiacomo AF, et al.: Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology 1996, 47:343–346. DOI: 10.1016/S0090-4295(99)80450-6
30. Riehmann M, Rhodes PR, Cook TD, et al.: Analysis of variation in prostate-specific antigen values. Urology 1993, 42:390–397. DOI: 10.1016/0090-4295(93)90364-G
31. Roehrborn CG, Pickens GJ, Carmody T: Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology 1996, 47:59–66. DOI: 10.1016/S0090-4295(99)80383-5
32. Mettlin C, Littrup PJ, Kane RA, et al., for the Investigators of the American Cancer Society National Prostate Cancer Detection Project: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer 1994, 74:1615–1620. DOI: 10.1002/1097-0142(19940901)74:5<1615::AID-CNCR2820740520>3.0.CO;2-6
33. Smith DS, Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994, 152:1163–1167.
34. Lujan M, Paez A, Sanchez E, et al.: Prostate specific antigen variation in patients without clinically evident prostate cancer. J Urol 1999, 162:1311–1313. DOI: 10.1016/S0022-5347(05)68273-0
35. Harris CH, Dalkin BL, Martin E, et al.: Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng/mL or less. J Urol 1997, 157:1740–1743. DOI: 10.1016/S0022-5347(01)64848-1
36. Yuan JJ, Coplen DE, Petros JA, et al.: Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate-specific antigen levels. J Urol 1992, 147:810–814.